Literature DB >> 28477730

Classical and non-classical causes of GH deficiency in adults.

F Tanriverdi1, F Kelestimur2.   

Abstract

Growth hormone deficiency (GHD) can develop due to a variety of conditions, and may occur either as isolated or multiple pituitary hormone deficiencies. It has been previously demonstrated that GH is one of the most frequent hormonal deficiencies in adult patients with hypopituitarism. The most frequent classical causes of adult-onset GHD (AO-GHD) are pituitary adenomas and/or their treatment. However, during the last decade an increasing number of studies from different parts of the world have revealed that non-tumoural causes of hypopituitarism are more common than previously known. Therefore, in this review our aim is to briefly summarize the classical and non-classical acquired causes of GHD in adults.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Sheehan's syndrome; growth hormone deficiency; hypopituitarism; sports-related head trauma; traumatic brain injury

Mesh:

Substances:

Year:  2017        PMID: 28477730     DOI: 10.1016/j.beem.2017.02.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  8 in total

1.  Anti-Pituitary and Anti-Hypothalamus Autoantibody Associations with Inflammation and Persistent Hypogonadotropic Hypogonadism in Men with Traumatic Brain Injury.

Authors:  Sushupta M Vijapur; Zhihui Yang; David J Barton; Leah Vaughan; Nabil Awan; Raj G Kumar; Byung-Mo Oh; Sarah L Berga; Kevin K Wang; Amy K Wagner
Journal:  J Neurotrauma       Date:  2020-04-13       Impact factor: 5.269

Review 2.  The Hypothalamic-Pituitary Axis and Autoantibody Related Disorders.

Authors:  Cristina Cocco; Carla Brancia; Giulia Corda; Gian-Luca Ferri
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

Review 3.  Update on GH therapy in adults.

Authors:  Cesar Luiz Boguszewski
Journal:  F1000Res       Date:  2017-11-16

4.  Somatropin therapy in italian adults with growth hormone deficiency.

Authors:  Flavia Pricci; Daniela Rotondi; Marika Villa; Arianna Valerio; Elvira Agazio; Paolo Roazzi
Journal:  BMC Endocr Disord       Date:  2022-03-03       Impact factor: 2.763

5.  PEGylated Recombinant Human Growth Hormone Jintrolong® Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients.

Authors:  Wei Wu; Juan Zhou; Chuandong Wu; Qian Zhou; Xiaoyu Li; Yanlin Zhang; Conglin Zuo; Jun Yin; Ling Hou; Shuyang Wang; Hongyang Gao; Tianhong Luo; Lei Jin; Enhong Zhong; Yingwu Wang; Xiaoping Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-15       Impact factor: 6.055

6.  Copeptin in Growth Hormone-Treated Patients.

Authors:  Anna Sjöström; Simona I Chisalita; Charlotte Höybye
Journal:  J Clin Med       Date:  2022-09-20       Impact factor: 4.964

Review 7.  Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile.

Authors:  Balázs Ratku; Veronika Sebestyén; Annamária Erdei; Endre V Nagy; Zoltán Szabó; Sándor Somodi
Journal:  Pituitary       Date:  2022-02-01       Impact factor: 4.107

Review 8.  Individual sensitivity to growth hormone replacement in adults.

Authors:  Cesar Luiz Boguszewski
Journal:  Rev Endocr Metab Disord       Date:  2020-10-07       Impact factor: 6.514

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.